Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[CD34+ cells: biological aspects]

F Benedetti1

  • 1Cattedra di Ematologia, Università di Verona.

Tumori
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

CD34+ cells are crucial for reconstituting the hematopoietic system post-transplant. Mobilizing and collecting these stem cells, particularly from peripheral blood, offers faster recovery but raises concerns about tumor contamination, driving the development of purification methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Family History and Solar Insolation in Bipolar I Disorder.

Acta psychiatrica Scandinavica·2026
Same author

Dissecting heterogeneity in cortical thickness abnormalities in major depressive disorder: a large-scale ENIGMA MDD normative modelling study.

bioRxiv : the preprint server for biology·2025
Same author

Understanding, predicting, and treating depression in pregnancy to improve mothers' and offspring's mental health outcomes: The HappyMums study.

Brain, behavior, & immunity - health·2025
Same author

Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia.

Blood cell therapy·2024
Same author

Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same journal

End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

Tumori·2026
Same journal

Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

Tumori·2026
Same journal

Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

Tumori·2026
Same journal

Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

Tumori·2026
Same journal

Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

Tumori·2026
Same journal

Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.

Tumori·2026
See all related articles

Area of Science:

  • Hematology and Immunology
  • Stem Cell Biology
  • Oncology

Context:

  • The CD34 antigen identifies hematopoietic stem and progenitor cells (HSPCs), essential for blood system regeneration.
  • Physiological levels of CD34+ cells are low in bone marrow, cord blood, and peripheral blood.
  • Growth factors and chemotherapy can significantly mobilize CD34+ cells into peripheral blood for collection.

Purpose:

  • To review the role, mobilization, collection, and clinical applications of CD34+ cells in hematopoietic stem cell transplantation (HSCT).
  • To discuss the challenges of tumor contamination in peripheral blood stem cell collections and the development of purging techniques.
  • To explore the potential of CD34+ cells as a target for gene therapy.

Summary:

  • CD34+ cells are critical for reconstituting myeloid and lymphoid systems after myeloablative treatment, making them valuable in autologous and allogeneic HSCT.

Related Experiment Videos

  • Peripheral blood stem cell transplantation (PBSCT) using mobilized CD34+ cells leads to faster hematopoietic recovery compared to traditional bone marrow transplantation.
  • Tumor cell contamination in PBSC products is a significant concern, necessitating the development of effective stem cell purging and CD34+ positive selection methods.

    • Impact:

    • Peripheral blood stem cell transplantation has become a widely used and safe procedure for treating various cancers.
    • Advancements in stem cell processing and purging techniques aim to improve transplant outcomes by reducing tumor relapse.
    • Enriched CD34+ cell populations offer promising avenues for future gene therapy applications in hematological disorders and other diseases.